ERK

Extracellular signal regulated kinases

ERK

ERK Isoform Specific Products:

ERK Isoform Comparison

ERK Related Products (442)
Antibodies (22)
ERK Isoform Comparison

By Effects:	Control (1) Inhibitors (287) Agonists (5) Degrader (1) Activators (92) Modulators (6) Chemical (1) Inducers (9)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-18723

Yoda 1	Activator	99.98%
Yoda 1 is a potent and selective Piezo1 agonist. Yoda 1 activates purified Piezo1 channels. Yoda 1 potently inhibits macropinocytosis induced by epidermal growth factor (EGF). Yoda 1 enhances Ca²⁺ influx followed by activation of the calcium-activated potassium channel KCa3.1 and inhibition of Rac1 activation.

HY-12028

PD98059	Inhibitor	99.96%
PD98059 is a potent and selective MEK inhibitor with an IC₅₀ of 5 µM. PD98059 binds to the inactive form of MEK, thereby preventing the activation of MEK1 (IC₅₀ of 2-7 µM) and MEK2 (IC₅₀ of 50 µM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC₅₀ of 4 μM) and AHR transformation (IC₅₀ of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy.

HY-50846

SCH772984	Inhibitor	99.83%
SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-na?ve and MAPK inhibitor-resistant cells containing BRAF or RAS mutations.

HY-19696

Tauroursodeoxycholate	Inhibitor	99.93%
Tauroursodeoxycholate (Tauroursodeoxycholic acid) is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-100489

TBHQ	Activator	99.89%
TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma.

HY-402361

TERT activator-1		99.50%
TERT activator-1 is a small molecule activator of telomerase reverse transcriptase (TERT). TERT activator-1 promotes TERT transcription through the MEK/ERK/AP-1 signaling cascade. TERT activator-1 promotes adult neurogenesis and enhances neuromuscular function. TERT activator-1 reduces cellular senescence and systemic inflammation in aged mice, and can be used in the study of aging.

HY-168438

ERBB agonist-1	Activator	99.16%
ERBB agonist-1 (Compound EF-1) is an agonist for ERBB4, that activates the ERBB4 signaling pathway by inducing dimerization of the ERBB4 receptor with an EC₅₀ of 10.5 μM. ERBB agonist-1 induces phosphorylation of Akt and ERK1/2, reduces the collagen expression in cardiac fibroblasts, inhibits H₂O₂-induced cardiomyocyte death and Ang II (HY-13948)-induced cardiomyocyte hypertrophy. ERBB agonist-1 prevents fibrosis and exhibits cardioprotective efficacy in mouse models.

HY-W004283R

Pentadecanoic acid (Standard)	Inhibitor
α-Linolenic acid (Standard) is the analytical standard of α-Linolenic acid. This product is intended for research and analytical applications. α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer.

HY-D0886

β-Glycerophosphate disodium salt pentahydrate	Activator	99.81%
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells.

HY-15816

Ulixertinib	Inhibitor	99.95%
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.

HY-N0431

Astragaloside IV	Inhibitor	99.93%
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

HY-N0003

Honokiol	Activator	99.90%
Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier.

HY-156498

RMC-7977	Inhibitor	99.48%
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (K_d = 195 nM) and KRAS (G12V) (K_d = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS^G12C cancer models, and demonstrates good tolerability across various RAS cancer models.

HY-108635

C16-PAF	Activator	99.85%
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.

HY-Y0337

L-Cysteine	Activator
L-Cysteine (Cysteine) is an orally active conditionally essential amino acid with hypoglycemic effects, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine promotes the proliferation and differentiation of neural stem cells via the CBS/H2S pathway. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans. L-Cysteine can be used as an anorectic agent.

HY-19696A

Tauroursodeoxycholate sodium	Inhibitor	98.40%
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

HY-101494

Temuterkib	Inhibitor	99.94%
Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC₅₀ of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

HY-N2329

Piperlongumine	Inhibitor	99.87%
Piperlongumine is a alkaloid, possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway. Piperlongumin could be used in the study of migrasome.

HY-15947

Ravoxertinib	Inhibitor	99.75%
Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC₅₀ of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.

HY-153346

Elironrasib	Inhibitor	99.65%
Elironrasib is an orally active and covalent inhibitor of KRAS^G12C(ON). Elironrasib forms a tri-complex within tumor cells between KRAS^G12C(ON) and cyclophilin A (CypA). Thus, Elironrasib prevents KRAS^G12C(ON) from signaling via steric blockade of RAS effector binding. Elironrasib inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. Elironrasib also inhibits the proliferation of KRAS^G12C mutant cells with a median IC₅₀ of 0.11 nM.

Yoda 1		ERK1	ERK2			99.98%
PD98059		ERK1	ERK2			99.96%
SCH772984		ERK1, IC₅₀: 4 nM	ERK2, IC₅₀: 1 nM			99.83%
Tauroursodeoxycholate	ERK					99.93%
TBHQ	ERK					99.89%
TERT activator-1		ERK1	ERK2			99.50%
β-Glycerophosphate disodium salt pentahydrate		ERK1	ERK2			99.81%
Ulixertinib			ERK2, IC₅₀: 0.3 nM (at K_M ATP (60 μM))			99.95%
Astragaloside IV		ERK1	ERK2			99.93%
Honokiol		ERK1	ERK2			99.90%
C16-PAF	ERK					99.85%
L-Cysteine		ERK1	ERK2
Tauroursodeoxycholate sodium	ERK					98.40%
Temuterkib		ERK1, IC₅₀: 5 nM	ERK2, IC₅₀: 5 nM			99.94%
Piperlongumine		ERK1	ERK2			99.87%
Ravoxertinib		ERK1, IC₅₀: 6.1 nM	ERK2, IC₅₀: 3.1 nM			99.75%
β-Glycerophosphate disodium salt hydrate		ERK1	ERK2			≥98.0%
Lidocaine	ERK					99.96%
Gamma-Linolenic acid		ERK1	ERK2			99.80%
Lysophosphatidylcholines		ERK1	ERK2			≥99.0%
trans-Zeatin	ERK					99.83%
Fucoxanthin			ERK2			98.99%
FR 180204		ERK1, Ki: 0.31 μM ERK1, IC₅₀: 0.51 μM	ERK2, Ki: 0.14 μM ERK2, IC₅₀: 0.33 μM			99.65%
ASN007		ERK1	ERK2			99.70%
6-OAU	ERK					99.91%
Pachymic acid	ERK					99.94%
Lidocaine hydrochloride	ERK					99.96%
BIX02189				ERK5, IC₅₀: 59 nM		99.99%
LM22B-10	ERK					99.92%
MK-8353		ERK1, IC₅₀: 23 nM	ERK2, IC₅₀: 8.8 nM			98.13%
XMD8-92				BMK1, Kd: 80 nM		99.67%
VX-11e			ERK2, Ki: 2 nM			99.17%
Peiminine		ERK1	ERK2			99.94%
Peramivir		ERK1	ERK2			99.32%
AG126			ERK2			≥98.0%
ASTX029		ERK1	ERK2			99.86%
Broussonin E	ERK					98.18%
AX-15836				ERK5, IC₅₀: 8 nM		99.68%
ERK1/2 inhibitor 1			ERK2, IC₅₀: 3.0 nM			99.79%
Pluripotin		ERK1, Kd: 98 nM				98.86%
Cafestol			ERK2			99.91%
CHPG sodium salt	ERK					99.25%
H-Ile-Lys-Val-Ala-Val-OH		ERK1	ERK2			99.42%
Lidocaine (Standard)	ERK					99.85%
Tizaterkib			ERK2, IC₅₀: 0.6 nM			99.31%
CC-90003		ERK1	ERK2			99.71%
Ravoxertinib hydrochloride		ERK1, IC₅₀: 6.1 nM	ERK2, IC₅₀: 3.1 nM			99.93%
Rineterkib		ERK1	ERK2			99.83%
DEL-22379			ERK2, IC₅₀: 0.5 μM			99.69%
ERK5-IN-1				ERK5, IC₅₀: 87 nM		99.33%
MAP855	ERK, EC₅₀: 5 nM					98.48%
JWG-071				ERK5, IC₅₀: 88 nM		99.15%
Methylnissolin		ERK1	ERK2			99.86%
KO-947		ERK1	ERK2			99.61%
Mogrol		ERK1	ERK2			99.76%
XMD17-109				ERK5, IC₅₀: 162 nM		99.20%
ERK5-IN-2				ERK5, IC₅₀: 0.82 μM ERK5 MEF2D, IC₅₀: 3 μM		98.96%
CK2/ERK8-IN-1					ERK8, IC₅₀: 0.5 μM	≥99.0%
β-Neo-Endorphin		ERK1	ERK2			99.32%
BIX02188				ERK5, IC₅₀: 810 nM		99.85%
CHPG	ERK					99.51%
Magnolin		ERK1, IC₅₀: 87 nM	ERK2, IC₅₀: 16.5 nM			99.98%
HIOC	ERK					99.94%
Sanggenon C	ERK					98.50%
4-Methylbenzylidene camphor		ERK1	ERK2			99.87%
Corynoxeine		ERK1	ERK2			99.97%
ASN007 benzenesulfonate		ERK1	ERK2			99.72%
ERK-IN-4			ERK2, Kd: 5 μM			99.61%
AT-533		ERK1	ERK2			98.86%
Myristicin	ERK					99.89%
Loureirin B	ERK					99.16%
Cearoin	ERK					≥98.0%
CKLF1-C27		ERK1	ERK2			98.46%
Methylthiouracil		ERK1	ERK2			≥98.0%
Longdaysin			ERK2, IC₅₀: 52 μM			99.83%
2,5-Dihydroxyacetophenone		ERK1	ERK2			99.89%
Deltonin		ERK1	ERK2			99.94%
Enniatin B1	ERK					99.34%
Omtriptolide	ERK
Anti-inflammatory agent 35	ERK					99.77%
[Tyr8] Bradykinin		ERK1	ERK2			99.61%
BAY885				ERK5, IC₅₀: 35 nM		99.27%
Lidocaine hydrochloride hydrate	ERK					99.90%
ML192		ERK1	ERK2
Isoprocurcumenol	ERK
EVT801	ERK, IC₅₀: 13 nM
SHR2415		ERK1, IC₅₀: 2.8 nM	ERK2, IC₅₀: 5.9 nM			98.63%
ERK1/2 inhibitor 9		ERK1	ERK2
Syk-IN-6		ERK1	ERK2
Hypothemycin		ERK1, Ki: 8.4 μM	ERK2, Ki: 2.4 μM			≥98.0%
ERK5-IN-5				ERK5		99.05%
PT-262	ERK					99.21%
Bohemine			ERK2, IC₅₀: 52 μM			98.93%
Sugiol		ERK1	ERK2			99.88%
ERK2 IN-1			ERK2, IC₅₀: 7 nM
ERK-IN-2			ERK2, IC₅₀: 1.8 nM
ERK5-IN-3				ERK5, IC₅₀: 6 ± 1 nM
Aloisine A		ERK1, IC₅₀: 18 μM	ERK2, IC₅₀: 22 μM
ZINC12409120	ERK, IC₅₀: 5 μM
ERK-IN-7		ERK1, IC₅₀: 5 nM	ERK2, IC₅₀: 7 nM
ERK1/2 inhibitor 13		ERK1, IC₅₀: 91.71 nM	ERK2, IC₅₀: 97.87 nM
ERK-IN-2 free base			ERK2, IC₅₀: 1.8 nM
DCZ19931		ERK1	ERK2
ERK-IN-8			ERK2, IC₅₀: ≤50 nM
MHJ-627				ERK5
ERK2 IN-5			ERK2, Ki: 86 nM
PPM-3				ERK5, IC₅₀: 62.4 ± 18. nM
Enniatin B	ERK					99.10%
ERK2-IN-4			ERK2, Ki: 0.006 μM
ERK2 allosteric-IN-1			ERK2, IC₅₀: 11 μM
CKLF1-C27 TFA		ERK1	ERK2
Enniatin A1	ERK
Anti-inflammatory agent 31		ERK1	ERK2
ERK1/2 inhibitor 10		ERK1, IC₅₀: 0.11 nM	ERK2, IC₅₀: 0.8 nM
Myristoyl-MEK1 Derived Peptide Inhibitor 1	ERK, IC₅₀: 13 μM (The in vivo inhibitory potency is determined in both PMA-treated NIH 3T3 cells and NGF-stimulated PC12 cells.)		ERK2, IC₅₀: 10 μM (The in vitro inhibitory potency of the peptides is measured based on their ability to inhibit MEK1-mediated phosphorylation of ERK2. )
CXJ-2	ERK
MK2-IN-5		ERK1	ERK2
Cudraflavone B	ERK
ERK5-IN-4				ERK5
Anticancer agent 231		ERK1	ERK2
ERK5-IN-6	ERK
Phenylhydroquinone		ERK1	ERK2
Tizaterkib (hexanedioic acid)			ERK2, IC₅₀: 0.6 nM
Methyl helicterate		ERK1	ERK2

Name
Email *

	Sorry, but the email address you supplied was invalid.

ERK

ERK

ERK Isoform Specific Products:

ERK Isoform Specific Products:

ERK Related Products (442)

Antibodies (22)

ERK Isoform Comparison

ERK Related Products (442):